chevron_leftBack
As of 7 June 2026, Onco-Innovations Ltd. has a market cap of $49.11M USD, ranking #30724 globally and #952 in Canada.
It ranks #2776 in the Healthcare sector, and #536 in the Biotechnology industry.
Key Stats
Market Cap
$49.11MUSD
68.5M CAD
Enterprise Value
$48.33MUSD
67.41M CAD
Revenue (TTM)
$110.88KUSD
154.67K CAD
Net Income (TTM)
-$10.7MUSD
-14.92M CAD
PS Ratio
442.9
PB Ratio
176.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas O’Shaughnessy
open_in_new
Website
oncoinnovations.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 7% | -20% | 109% | 0.8% | -9.7% | -16% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ONCO
Onco-Innovations Ltd
ISIN: CA68237C1059
|
1.23 CAD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Onco-Innovations Ltd.
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AUPH
|
$1.99B
4K%
|
7.4
|
|
NASDAQ: ABCL
|
$1.16B
2K%
|
-
|
|
TSX: EPRX
|
$430.76M
777%
600.89M CAD
|
-
|
|
TSXV: NGEN
|
$294.06M
499%
410.19M CAD
|
-
|
|
NEO: CYBN
|
$253.15M
416%
353.13M CAD
|
-
|
|
TSX: CRDL
|
$149.17M
204%
208.08M CAD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
371K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
326K%
|
19.0
|
|
EBR: ARGX
|
$48.08B
98K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.48B
90K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$43.01B
87K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.72B
87K%
33.71B CHF
|
37.2
|
chevron_leftBack